bay-63-2521 and Placenta-Diseases

bay-63-2521 has been researched along with Placenta-Diseases* in 1 studies

Other Studies

1 other study(ies) available for bay-63-2521 and Placenta-Diseases

ArticleYear
Stimulation of soluble guanylate cyclase diminishes intrauterine growth restriction in a rat model of placental ischemia.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2021, 02-01, Volume: 320, Issue:2

    Placental ischemia in preeclampsia (PE) results in hypertension and intrauterine growth restriction (IUGR). Stimulation of soluble guanylate cyclase (sGC) reduces blood pressure in the clinically relevant reduced uterine perfusion pressure (RUPP) rat model of PE, implicating involvement in RUPP-induced hypertension. However, the contribution of sGC in the development of IUGR in PE is not known. Thus, this study demonstrated the efficacy of Riociguat, an sGC stimulator, in IUGR reversion in the RUPP rat model of PE, and tested the hypothesis that improvement in fetal weight occurs in association with improvement in placental perfusion, placental morphology, and placental nutrient transport protein expression. Sham or RUPP surgery was performed at gestational day 14 (G14) with administration of vehicle (Sham or RUPP) or the sGC stimulator (Riociguat, 10 mg/kg/day sc; sGC-treated) until G20. Fetal weight was reduced (

    Topics: Animals; Female; Fetal Growth Retardation; Gene Expression Regulation, Enzymologic; Ischemia; Placenta Diseases; Pre-Eclampsia; Pregnancy; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; Soluble Guanylyl Cyclase; Uterine Artery

2021